US52490G1022 - ADR
Legend Biotech shares surge as EU drug regulator panel recommends label expansion for Carvykti in multiple myeloma patients.
Johnson & Johnson(JNJ) wins endorsement in Europe to expand labeling for its CAR-T therapy Carvykti marketed with Legend Biotech (LEGN). Read more here.
Legend Biotech (LEGN) and J&J's (JNJ) multiple myeloma treatment Carvykti get label update to include a warning on blood cancer. Read more here.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation ("Legend" or the "Company") (NASDAQ: LEGN). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation ("Legend" or the "Company") (NASDAQ: LEGN). Such...
The FDA on Tuesday said it was looking into reports of T-cell malignancies in patients who have been treated with CAR-T cell immunotherapies. Read more here.
The FDA on Tuesday said it was looking into reports of T-cell malignancies in patients who have been treated with CAR-T cell immunotherapies. Read more here.
Legend Biotech reports Q3 2023 results with a beat in GAAP EPS but miss in revenue, reflecting a 250.9% YoY growth and a -$0.17 EPS, respectively.
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.